Rheumatoid Arthritis, Sleep Quality, Transcutaneous Electric Nerve Stimulation
Conditions
Brief summary
The purpose of this clinical trial is to determine whether transcutaneous auricular vagus nerve stimulation (taVNS) is suitable for improving sleep disorders in patients with rheumatoid arthritis (RA). It will also evaluate the safety of taVNS. The main questions it aims to answer are: Can taVNS improve the sleep quality of RA patients? What medical issues might RA patients experience while receiving taVNS treatment? Researchers will compare taVNS with a placebo (a similar substance that does not contain the actual treatment) to see if taVNS is effective in improving sleep disorders in RA patients. Participants will: Receive taVNS or sham stimulation daily for 4 weeks Keep a daily sleep diary and visit the hospital once a week for check-ups and tests Record their sleep quality and related symptoms This study aims to provide a new, safe, and effective non-drug therapy for sleep disorders related to RA.
Interventions
Treatment using the Huatuo electronic acupuncture device (model SDZ-IIB) with electrodes placed on the auricular points related to the heart and kidney. Pulsed wave type is sparse-dense wave, with a frequency of 20Hz and intensity set to the highest level tolerable without pain. Patients will perform self-treatment at home for 30 minutes, twice daily, for 5 days a week over 4 weeks.
Treatment using the same Huatuo electronic acupuncture device with electrodes placed on different ear points (over the ear helix). The device settings (pulse type, frequency, intensity) are the same as the experimental group but do not correspond to traditional acupuncture points. Patients will also perform self-treatment at home as per the same schedule as the experimental group.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Meets the 2010 ACR/EULAR criteria for rheumatoid arthritis. 2. Poor sleep quality (PSQI score \> 7). 3. Disease activity is moderate to low or in remission (DAS28 score ≤ 5.1). 4. No risk of sleep apnea (STOP-Bang questionnaire \< 3). 5. Aged between 18 and 70. 6. The type and dosage of rheumatoid arthritis medication must be stable for at least 4 weeks. 7. Signed informed consent.
Exclusion criteria
1. People with acute infectious diseases, whether generalized or localized; 2. Those with severe internal organ diseases (such as coronary heart disease, arrhythmia, malignant tumors, renal failure, etc.); 3. Those working night shifts during the intervention period; 4. Those with other rheumatic diseases such as systemic lupus erythematosus, fibromyalgia, and Sjogren's syndrome; 5. Those undergoing treatment with steroids, sleeping pills, antidepressants, or antipsychotics; 6. Pregnant and breastfeeding women; 7. Those who cannot tolerate transcutaneous auricular electrostimulation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pittsburgh Sleep Quality Index(PSQI) | Baseline, week1, week2, week3, week4 | Scores on the Pittsburgh Sleep Quality Index (PSQI) range from 0 to 21, with higher scores indicating worse sleep quality. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Medical outcomes study sleep scale(MOS-SS) | Baseline,week4 | The MOS-SS Sleep Scale consists of 12 items and requires respondents to recall their sleep conditions over the past 4 weeks. Based on the scores for each item, the key indicators' scores are calculated. |
| Epworth sleepiness scale(ESS) | Baseline,week4 | The ESS consists of 8 questions, each describing a common daily activity. For each activity, respondents rate their tendency to doze off or fall asleep. The total score ranges from 0 to 24. |
| the Multidimensional Fatigue Inventory-20 (MFI-20) | Baseline,week4 | The Multidimensional Fatigue Inventory-20 (MFI-20) measures fatigue severity. The MFI-20 total score ranges from 0 to 80, with higher scores indicate more severe fatigue. |
| Tender joint count(TJC) | Baseline, week2, week4 | Tender Joint Count is a key clinical indicator in evaluating rheumatoid arthritis (RA). It measures the number of joints where patients feel pain upon touch or movement, helping to assess the disease's activity and severity. It involves 28 joints throughout the body. |
| Consensus Sleep Diary-Core(CSD) | Baseline, week1, week2, week3, week4 | The Consensus Sleep Diary is primarily used to record and analyze sleep patterns and quality to help identify insomnia issues. While the Consensus Sleep Diary itself does not directly provide a scoring system, the recorded data can be used to calculate key sleep parameters. These parameters can be used to assess the severity of insomnia and the effectiveness of treatments. |
| Visual analogue scale(VAS) for pain | Baseline, week1, week2, week3, week4 | Pain VAS, range, 0 to 10 cm, where higher scores indicated the perceived pain to be more severe. |
| Disease Activity Score - 28 joints(DAS-28 ESR/CRP) | Baseline,week4 | DAS28 helps monitor RA progression, guide treatment, and is used in research. It provides a reliable measure for managing RA effectively. |
| Health Assessment Questionnaire(HAQ) | Baseline,week4 | The Health Assessment Questionnaire (HAQ) has a total of 20 items, each scored to reflect the patient's functional ability in daily life. The scores for each item are averaged, resulting in a total score ranging from 0 to 3. |
| Hospital Anxiety and Depression Scale(HADS) | Baseline,week4 | The Hospital Anxiety and Depression Scale (HADS) is a commonly used tool for screening and assessing anxiety and depression in general medical patients. The scale consists of 14 items. Each item is scored from 0 to 3 based on the severity of the symptoms, with a total score of 28. |
| Swollen joint count(SJC) | Baseline, week2, week4 | Swollen Joint Count (SJC) is another key clinical indicator for evaluating rheumatoid arthritis (RA). It measures the number of joints that are swollen due to inflammation, involving a total of 28 joints throughout the body. |
Countries
China